Development of a pioneering self-monitoring solution in live animals to minimize the presence of antibiotic residues in the food chain of the French-Spanish cross-border zone (Q4295679)
Jump to navigation
Jump to search
Project Q4295679 in France, Spain
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Development of a pioneering self-monitoring solution in live animals to minimize the presence of antibiotic residues in the food chain of the French-Spanish cross-border zone |
Project Q4295679 in France, Spain |
Statements
839,519.85 Euro
0 references
1,291,569.0 Euro
0 references
65.0 percent
0 references
1 January 2018
0 references
31 December 2020
0 references
Universidad De Zaragoza-Instituto Agroalimentario De Aragón
0 references
43°30'56.27"N, 1°29'58.45"E
0 references
42°27'47.38"N, 2°25'41.34"W
0 references
41°39'9.40"N, 0°59'2.51"W
0 references
43°31'58.12"N, 1°29'27.67"E
0 references
42°40'56.35"N, 2°53'56.00"E
0 references
43°14'18.20"N, 2°53'35.05"W
0 references
41°38'31.42"N, 0°54'5.44"W
0 references
The WHO (2016) lists antibiotic resistance as one of the 3 major problems facing humanity. In Europe it causas 25000 annual deaths and losses of 1500M€. The international initiative One Health proposes the reduction of the use of these medicines in the fields: clinical and veterinary. It should be noted that the livestock sector consumes 70% of the antibiotics sold worldwide. The project aims to contribute to improving the management of the use of antibiotics in the livestock sector (bovine, ovine, porcine and avian) and thus reduce the risk of their presence in the food chain. The main objective is the development of innovative analytical tools for the rapid detection of residues of antibiotics in live animals. This pioneering initiative will allow farmers and food industry in the region to benefit from a unique solution for the self-control of these residues in farm and slaughterhouse, which will guarantee a reduction of the health risks associated with meat production. In addition, the two participating biotechnology companies will position themselves globally at the forefront of this field of diagnosis. All this will be possible thanks to the participation of specialists from the region in pharmacology, microbiology and biosensors and the close public-private partnership with biotechnology companies that will enable to put on the market the developed systems (English)
0 references